🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER

RecruitingNAAges 18 Years - anyFemaleEuropean Institute of Oncology
NCT07690540 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In recent years, the introduction of immune checkpoint inhibitors (ICI) in combination with chemotherapy has significantly changed the management of advanced and recurrent Endometrial Cancer (EC). Despite these advances, responses to immunotherapy remain heterogeneous. Not all patients with mismatch repair-deficient (dMMR) tumors derive durable benefit, while a subset of mismatch repair-proficient (pMMR) tumors may respond. In addition, ICI treatment is associated with relevant costs and immune-related toxicities, highlighting the need for improved patient selection. To date, no validated predictive biomarkers beyond mismatch repair (MMR) status are available, reflecting limited understanding of the biological mechanisms underlying sensitivity and resistance to immunotherapy in EC. This study aims to assess and integrate molecular and epigenetic features to identify prognostic and pred

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed advanced or recurrent endometrial carcinoma or carcinosarcoma * No prior treatment with immune checkpoint inhibitors * Availability of paired fresh-frozen and FFPE tumor samples * Provision of written informed consent for participation in translational research Exclusion Criteria: * Refusal or inability to provide informed consent by the patient or legal representative * Mesenchymal tumors or epithelial tumors of non-endometrial origin (e.g., ovarian cancer) * Active treatment with immunomodulatory agents at the time of sample collection (e.g., immunotherapy for autoimmune disease) * Known positivity for HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV)
💊

What it tests

  • Prospective exploratory cohort
📍

Where

1 site
European Institute of Oncology
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy